Loading…
Loading…
RMD · NYSE · Healthcare
“At 22.4 times earnings, RMD's valuation demands exceptional growth consistency to justify the premium over its medical device fundamentals and competitive moat durability.”
— In the voice of Graham
Project future earnings using analyst estimates and historical growth rates. Model 5-year earnings trajectories.
Market Cap
$33.26B
P/E Ratio
22.39
Forward P/E
—
EPS
$2.69
PEG Ratio
1.55
Book Value
$43.34
Dividend Yield
0.26%
Profit Margin
27.59%
ROE
6.21%
Use the interactive growth projection with pre-loaded data for Resmed Inc. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for RMD: